Abbott (ABT) is expected to report Q1 earnings before the market open on Wednesday, April 18 with a conference call scheduled for 9:00 am ET.
Analysts are looking for EPS of $1.00 on revenue of $9.36B. The consensus range is 97c-$1.07 for EPS, and $9.24B-$9.67B for revenue, according to First Call. After reporting slightly better-than-expected EPS and disappointing revenue numbers in Q4, the company gave a forecast of FY12 EPS $4.95-$5.05, consensus $5.01. In the Q4 earnings conference call, it said it was on track to separate into two health care companies by the end of 2012. Investors will look to hear for an update on the planned split. In the previous quarter, Abbott announced FDA approval for its Absolute Pro and its FreeStyle InsuLinx Blood monitoring system, while receiving approval in Japan for its Xience Prime drug eluting stent. It had also received positive Phase 2 clinical trial results for Hepatitis C treatment and initiated two Phase 3 clinical trials for Humira. Humira contributed nearly 20% of the company's total revenues last year and investors will listen closely to its Q1 sales numbers as well.
Wells Fargo noted that the company's momentum will likely continue short-term. Deutsche Bank upgraded the company to Buy, and Jeffries kept its Buy rating.